Literature DB >> 15624111

Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis.

Shin Kwak1, Yukio Kawahara.   

Abstract

One plausible hypothesis for selective neuronal death in sporadic amyotropic lateral sclerosis (ALS) is excitotoxicity mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors, which are a subtype of ionotropic glutamate receptors. The Ca2+ conductance of AMPA receptors differs markedly depending on whether the GluR2 (or GluR-B) subunit is a component of the receptor. The properties of GluR2 are generated posttranscriptionally by RNA editing at the Q/R site in the putative second membrane domain (M2), during which the glutamine (Q) codon is substituted by an arginine (R) codon. AMPA receptors containing the unedited form of GluR2Q have high Ca2+ permeability in contrast to the low Ca2+ conductance of those containing the edited form of GluR2R. The role of Ca(2+)-permeable AMPA receptors, particularly GluR2 Q/R site RNA editing status, in neuronal death has been clearly demonstrated both in mice deficient in editing at the GluR2 Q/R site and in mice transgenic for an artificial Ca(2+)-permeable GluR2 subunit. We analyzed the expression level of mRNA of each AMPA receptor subunit in individual motor neurons, as well as the editing efficiency of GluR2 mRNA at the Q/R site in the single neuron level in control subjects and ALS cases. There was no significant difference as to the expression profile of AMPA receptor subunits or the proportion of GluR2 mRNA to total GluRs mRNA between normal subjects and ALS cases. By contrast, the editing efficiency varied greatly, from 0% to 100%, among the motor neurons of each individual with ALS, and was not complete in 44 of them (56%), whereas it remained 100% in normal controls. In addition, GluR2 editing efficiency was more than 99% in the cerebellar Purkinje cells of ALS, spinocerebellar degeneration and normal control groups. Thus, GluR2 underediting occurs in a disease specific and region selective manner. GluR2 modification by RNA editing is a biologically crucial event for neuronal survival, and its deficiency is a direct cause of neuronal death. Therefore, marked reduction of RNA editing in ALS motor neurons may be a direct cause of the selective motor neuron death seen in ALS. It is likely that the molecular mechanism underlying the deficiency in RNA editing is a reduction in the activity of ADAR2, a double- strand RNA specific deaminase. The restoration of this enzyme activity in ALS motor neurons may open the novel strategy for specific ALS therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15624111     DOI: 10.1007/s00109-004-0599-z

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  105 in total

Review 1.  Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded.

Authors:  J P Julien
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2.

Authors:  M Higuchi; S Maas; F N Single; J Hartner; A Rozov; N Burnashev; D Feldmeyer; R Sprengel; P H Seeburg
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

3.  Dramatic increase of the RNA editing for glutamate receptor subunits during terminal differentiation of clonal human neurons.

Authors:  F Lai; C X Chen; V M Lee; K Nishikura
Journal:  J Neurochem       Date:  1997-07       Impact factor: 5.372

4.  Selective RNA editing and subunit assembly of native glutamate receptors.

Authors:  R B Puchalski; J C Louis; N Brose; S F Traynelis; J Egebjerg; V Kukekov; R J Wenthold; S W Rogers; F Lin; T Moran
Journal:  Neuron       Date:  1994-07       Impact factor: 17.173

5.  Relative abundance of subunit mRNAs determines gating and Ca2+ permeability of AMPA receptors in principal neurons and interneurons in rat CNS.

Authors:  J R Geiger; T Melcher; D S Koh; B Sakmann; P H Seeburg; P Jonas; H Monyer
Journal:  Neuron       Date:  1995-07       Impact factor: 17.173

6.  Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis.

Authors:  J D Rothstein; M Van Kammen; A I Levey; L J Martin; R W Kuncl
Journal:  Ann Neurol       Date:  1995-07       Impact factor: 10.422

7.  Patterns of developmental expression of the RNA editing enzyme rADAR2.

Authors:  M A O'Connell; A P Gerber; R S Zukin
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

8.  RED2, a brain-specific member of the RNA-specific adenosine deaminase family.

Authors:  T Melcher; S Maas; A Herb; R Sprengel; M Higuchi; P H Seeburg
Journal:  J Biol Chem       Date:  1996-12-13       Impact factor: 5.157

9.  Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia.

Authors:  S Akbarian; M A Smith; E G Jones
Journal:  Brain Res       Date:  1995-11-20       Impact factor: 3.252

10.  VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.

Authors:  Mimoun Azzouz; G Scott Ralph; Erik Storkebaum; Lucy E Walmsley; Kyriacos A Mitrophanous; Susan M Kingsman; Peter Carmeliet; Nicholas D Mazarakis
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

View more
  79 in total

Review 1.  Activity regulation of adenosine deaminases acting on RNA (ADARs).

Authors:  Cesare Orlandi; Alessandro Barbon; Sergio Barlati
Journal:  Mol Neurobiol       Date:  2011-11-20       Impact factor: 5.590

Review 2.  Links between electrophysiological and molecular pathology of amyotrophic lateral sclerosis.

Authors:  Katharina A Quinlan
Journal:  Integr Comp Biol       Date:  2011-10-11       Impact factor: 3.326

Review 3.  Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis.

Authors:  Lee J Martin
Journal:  IDrugs       Date:  2010-08

Review 4.  Adenosine deaminases acting on RNA, RNA editing, and interferon action.

Authors:  Cyril X George; Zhenji Gan; Yong Liu; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2010-12-23       Impact factor: 2.607

Review 5.  A-to-I RNA editing and human disease.

Authors:  Stefan Maas; Yukio Kawahara; Kristen M Tamburro; Kazuko Nishikura
Journal:  RNA Biol       Date:  2006-01-12       Impact factor: 4.652

Review 6.  Probing the intermediacy of covalent RNA enzyme complexes in RNA modification enzymes.

Authors:  Stephanie M Chervin; Jeffrey D Kittendorf; George A Garcia
Journal:  Methods Enzymol       Date:  2007       Impact factor: 1.600

7.  Altered RNA editing in mice lacking ADAR2 autoregulation.

Authors:  Yi Feng; Christopher L Sansam; Minati Singh; Ronald B Emeson
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

Review 8.  Epigenetic regulation in Parkinson's disease.

Authors:  Catherine Labbé; Oswaldo Lorenzo-Betancor; Owen A Ross
Journal:  Acta Neuropathol       Date:  2016-06-29       Impact factor: 17.088

Review 9.  RNA-binding proteins in neurodegeneration: Seq and you shall receive.

Authors:  Julia K Nussbacher; Ranjan Batra; Clotilde Lagier-Tourenne; Gene W Yeo
Journal:  Trends Neurosci       Date:  2015-03-09       Impact factor: 13.837

10.  A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology.

Authors:  Takenari Yamashita; Takuto Hideyama; Kosuke Hachiga; Sayaka Teramoto; Jiro Takano; Nobuhisa Iwata; Takaomi C Saido; Shin Kwak
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.